Cited by 1,030Genetic Neurodegenerative DiseasesMitochondrial Function and PathologyHereditary Neurological Disorders

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines

Panov, Alexander V., Gutekunst, Claire-Anne, Leavitt, Blair R., Hayden, Michael R., Burke, James R., Strittmatter, Warren J., Greenamyre, J. Timothy·2002·Nature Neuroscience

DOI 10.1038/nn884

Open this paper in CoChat — free account

Abstract

Huntington's disease (HD) is caused by an expansion of exonic CAG triplet repeats in the gene encoding huntingtin protein (Htt), but the mechanisms by which this mutant protein causes neurodegeneration remain unknown. Here we show that lymphoblast mitochondria from patients with HD have a lower membrane potential and depolarize at lower calcium loads than do mitochondria from controls. We found a similar defect in brain mitochondria from transgenic mice expressing full-length mutant huntingtin, and this defect preceded the onset of pathological or behavioral abnormalities by months. By electron microscopy, we identified N-terminal mutant huntingtin on neuronal mitochondrial membranes, and by incubating normal mitochondria with a fusion protein containing an abnormally long polyglutamine repeat, we reproduced the mitochondrial calcium defect seen in human patients and transgenic animals. Thus, mitochondrial calcium abnormalities occur early in HD pathogenesis and may be a direct effect of mutant huntingtin on the organelle.

Integrity signals

Registry

Crossref · 10.1038/nn884

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes
MACDONALD, M. (1993) · Cell · doi:10.1016/0092-8674(93)90585-e · Cited by 8,366
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R. S., Sherer, T., MacKenzie, G. M., Garcia‐Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,770
Self-citation
A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. The Huntington's Disease Collaborative Research Group.
Shah, M. A., Datson, N. A., Srinidhi, L., Stanton, V. P., MacDonald, M. E., Allard, M. W., Youngman, S., Am, F., Mott, R., Draths, K., et al. (1993) · Cell · Cited by 3,055
Aggregation of Huntingtin in Neuronal Intranuclear Inclusions and Dystrophic Neurites in Brain
DiFiglia, M., Sapp, E., Chase, K. O., Davies, S. W., Bates, G. P., Vonsattel, J. P., & Aronin, N. (1997) · Science · doi:10.1126/science.277.5334.1990 · Cited by 2,439
Formation of Neuronal Intranuclear Inclusions Underlies the Neurological Dysfunction in Mice Transgenic for the HD Mutation
Davies, S. W., Turmaine, M., Cozens, B. A., DiFiglia, M., Sharp, A. H., Ross, C. A., Scherzinger, E., Wanker, E. E., Mangiarini, L., & Bates, G. P. (1997) · Cell · doi:10.1016/s0092-8674(00)80513-9 · Cited by 2,188
Mitochondrial Transport of Cations: Channels, Exchangers, and Permeability Transition
Bernardi, P. (1999) · Physiological Reviews · doi:10.1152/physrev.1999.79.4.1127 · Cited by 1,546
Aging, energy, and oxidative stress in neurodegenerative diseases
Beal, M. F. (1995) · Annals of Neurology · doi:10.1002/ana.410380304 · Cited by 1,434
Huntingtin-Encoded Polyglutamine Expansions Form Amyloid-like Protein Aggregates In Vitro and In Vivo
Scherzinger, E., Lurz, R., Turmaine, M., Mangiarini, L., Hollenbach, B., Hasenbank, R., Bates, G. P., Davies, S. W., Lehrach, H., & Wanker, E. E. (1997) · Cell · doi:10.1016/s0092-8674(00)80514-0 · Cited by 1,291 · cited 1×
“Consistent with the toxic 'gain-of-function' hypothesis, mutant Htt self-associates and forms aggregates in a polyglutamine length–dependent manne”
Background
Histone deacetylase inhibitors arrest polyglutamine-dependent neurodegeneration in Drosophila
Steffan, J. S., Bodai, L., Pallos, J., Poelman, M., McCampbell, A., Apostol, B. L., Kazantsev, A., Schmidt, E., Zhu, Y.-Z., Greenwald, M., et al. (2001) · Nature · doi:10.1038/35099568 · Cited by 1,228
Loss of Huntingtin-Mediated BDNF Gene Transcription in Huntington's Disease
Zuccato, C., Ciammola, A., Rigamonti, D., Leavitt, B. R., Goffredo, D., Conti, L., MacDonald, M. E., Friedlander, R. M., Silani, V., Hayden, M. R., et al. (2001) · Science · doi:10.1126/science.1059581 · Cited by 1,123
Self-citation

Flagged first, then by citations

Show all 35 references

Sorted by citations

Items 501–600 of 1,000

Mitophagy in Huntington's disease
Šonský, I., Vodička, P., Kepková, K. V., & Hansíková, H. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105147 · Cited by 42
Neuronal cell-based high-throughput screen for enhancers of mitochondrial function reveals luteolin as a modulator of mitochondria-endoplasmic reticulum coupling
Naia, L., Pinho, C. M., Dentoni, G., Liu, J., Leal, N. S., Ferreira, D. M. S., Schreiner, B., Filadi, R., Fão, L., Connolly, N. M. C., et al. (2021) · BMC Biology · doi:10.1186/s12915-021-00979-5 · Cited by 40
Increased glutathione levels in cortical and striatal mitochondria of the R6/2 Huntington's disease mouse model
Choo, Y. S., Mao, Z., Johnson, G. V. W., & Lesort, M. J. (2005) · Neuroscience Letters · doi:10.1016/j.neulet.2005.05.065 · Cited by 42
Neuroprotective mechanisms of brain‐derived neurotrophic factor against 3‐nitropropionic acid toxicity: therapeutic implications for Huntington's disease
Wu, C., Hwang, C., Chen, S., Yin, J., & Yang, D. (2010) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05628.x · Cited by 40
Attenuation of proinflammatory cytokines and apoptotic process by verapamil and diltiazem against quinolinic acid induced Huntington like alterations in rats
Kalonia, H., Kumar, P., & Kumar, A. (2010) · Brain Research · doi:10.1016/j.brainres.2010.11.060 · Cited by 41
Huntingtin fragmentation and increased caspase 3, 8 and 9 activities in lymphoblasts with heterozygous and homozygous Huntington's disease mutation
Maglione, V., Cannella, M., Gradini, R., Cislaghi, G., & Squitieri, F. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.011 · Cited by 40
A comprehensive perspective of Huntington’s disease and mitochondrial dysfunction
Dai, Y., Wang, H., Lian, A., Li, J., Zhao, G., Hu, S., & Li, B. (2023) · Mitochondrion · doi:10.1016/j.mito.2023.03.001 · Cited by 40
In Vitro Differentiation of Human Neural Progenitor Cells Into Striatal GABAergic Neurons
Lin, L., Yuan, J., Sander, B. O., & Golas, M. M. (2015) · Stem Cells Translational Medicine · doi:10.5966/sctm.2014-0083 · Cited by 41
Lipid Membranes Influence the Ability of Small Molecules To Inhibit Huntingtin Fibrillization
Beasley, M. A., Stonebraker, A. R., Hasan, I., Kapp, K. L., Liang, B. J., Agarwal, G., Groover, S. E., Sedighi, F., & Legleiter, J. A. (2019) · Biochemistry · doi:10.1021/acs.biochem.9b00739 · Cited by 39
Mitochondrial and Redox Modifications in Huntington Disease Induced Pluripotent Stem Cells Rescued by CRISPR/Cas9 CAGs Targeting
Lopes, C., Tang, Y., Anjo, S. I., Manadas, B. J., Onofre, I., de Almeida, L. P., Daley, G. Q., Schlaeger, T. M., & Rego, A. C. (2020) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2020.576592 · Cited by 40
Studying polyglutamine diseases in Drosophila
Xu, Z., Tito, A. J., Rui, Y., & Zhang, S. (2015) · Experimental Neurology · doi:10.1016/j.expneurol.2015.08.002 · Cited by 41
Huntington's disease: progress and potential in the field
Stack, E. C., & Ferrante, R. J. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.12.1933 · Cited by 39
Impaired mitochondrial homeostasis and neurodegeneration: towards new therapeutic targets?
Corona, J. C., & Duchen, M. R. (2014) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-014-9576-6 · Cited by 38
Mouse Models of Polyglutamine Diseases in Therapeutic Approaches: Review and Data Table. Part II
Switonski, P. M., Szlachcic, W. J., Gabka, A., Krzyżosiak, W. J., & Figiel, M. (2012) · Molecular Neurobiology · doi:10.1007/s12035-012-8316-3 · Cited by 38
The Role of Mitochondrial Calcium Signaling in the Pathophysiology of Cancer Cells
Sterea, A. M., & Hiani, Y. E. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-12457-1_30 · Cited by 38
Epigenetic regulation in Huntington's disease
Hyeon, J. W., Kim, A. H., & Yano, H. (2021) · Neurochemistry International · doi:10.1016/j.neuint.2021.105074 · Cited by 40
DNA instability in replicating Huntington's disease lymphoblasts
Cannella, M., Maglione, V., Martino, T., Ragona, G., Frati, L., Li, G., & Squitieri, F. (2009) · BMC Medical Genetics · doi:10.1186/1471-2350-10-11 · Cited by 38
Light and electron microscopic characterization of the evolution of cellular pathology in the Hdh(CAG)150 Huntington's disease knock-in mouse
Bayram-Weston, Z., Torres, E. M., Jones, L., Dunnett, S. B., & Brooks, S. P. (2011) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2011.03.014 · Cited by 39
Transglutaminase Activation in Neurodegenerative Diseases
Jeitner, T. M., Muma, N. A., Battaile, K. P., & Cooper, A. J. L. (2009) · Future Neurology · doi:10.2217/fnl.09.17 · Cited by 38
Soluble mutant huntingtin drives early human pathogenesis in Huntington’s disease
Miguez, A., Gomis, C., Vila, C., Tortajada, M., Fernández‐García, S., Bombau, G., Galofré, M., García-Bravo, M., Sanders, P., Fernández-Medina, H., et al. (2023) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-023-04882-w · Cited by 38
Sir2 is induced by oxidative stress in a yeast model of Huntington disease and its activation reduces protein aggregation
Sorolla, M. A., Nierga, C., Colman, M. J. R., Reverter‐Branchat, G., Arenas, A., Tamarit, J., Ros, J., & Cabiscol, E. (2011) · Archives of Biochemistry and Biophysics · doi:10.1016/j.abb.2011.04.002 · Cited by 37
Targeting TRPs in Neurodegenerative Disorders
Takada, Y., Numata, T., & Mori, Y. (2013) · Current Topics in Medicinal Chemistry · doi:10.2174/1568026611313030009 · Cited by 37
Use of human stem cells in Huntington disease modeling and translational research
Golas, M. M., & Sander, B. O. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.01.021 · Cited by 37
Mitochondrial and Redox-Based Therapeutic Strategies in Huntington's Disease
Fão, L., & Rego, A. C. (2020) · Antioxidants and Redox Signaling · doi:10.1089/ars.2019.8004 · Cited by 37
Roles of Long Non-coding RNAs in the Development of Aging-Related Neurodegenerative Diseases
Ni, Y., Xu, H., & Liu, Y. (2022) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2022.844193 · Cited by 37
Downstream mechanisms triggered by mitochondrial dysfunction in the basal ganglia: From experimental models to neurodegenerative diseases
Gubellini, P., Picconi, B., Filippo, M. D., & Calabresi, P. (2009) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2009.08.001 · Cited by 40
Compounds that extend longevity are protective in neurodegenerative diseases and provide a novel treatment strategy for these devastating disorders
Soo, S. K., Rudich, P. D., Traa, A., Harris-Gauthier, N., Shields, H. J., & Raamsdonk, J. M. V. (2020) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2020.111297 · Cited by 37
Mitochondrial and redox modifications in early stages of Huntington's disease
Lopes, C., Ferreira, I. L., Maranga, C., Beatriz, M., Mota, S. I., Sereno, J., Castelhano, J., Abrunhosa, A., Oliveira, F. P. M., Rosa, M. D., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102424 · Cited by 37
Self-citation
Unraveling the nexus of age, epilepsy, and mitochondria: exploring the dynamics of cellular energy and excitability
Xie, W., Koppula, S., Kale, M. B., Ali, L. S., Wankhede, N. L., Umare, M. D., Upaganlawar, A. B., Abdeen, A., Ebrahim, E., El‐Sherbiny, M., et al. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1469053 · Cited by 38
Rhodamine based plasmid DNA nanoparticles for mitochondrial gene therapy
Santos, J. M. A., de Sousa, F. P., Queiroz, J. A., & Costa, D. R. B. (2014) · Colloids and Surfaces B Biointerfaces · doi:10.1016/j.colsurfb.2014.06.003 · Cited by 36
Mitophagy and the therapeutic clearance of damaged mitochondria for neuroprotection
East, D. A., & Campanella, M. (2016) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2016.08.019 · Cited by 37
Expression of brain-derived neurotrophic factor in astrocytes - Beneficial effects of glatiramer acetate in the R6/2 and YAC128 mouse models of Huntington's disease
Reick, C., Ellrichmann, G., Tsai, T., Lee, D.-H., Wiese, S., Gold, R., Carsten Saft, C., & Linker, R. A. (2016) · Experimental Neurology · doi:10.1016/j.expneurol.2016.08.012 · Cited by 36
miR-196a Ameliorates Cytotoxicity and Cellular Phenotype in Transgenic Huntington’s Disease Monkey Neural Cells
Kunkanjanawan, T., Carter, R. L., Prucha, M. S., Yang, J., Parnpai, R., & Chan, A. W. S. (2016) · PLoS ONE · doi:10.1371/journal.pone.0162788 · Cited by 36
Selective Neuron Vulnerability in Common and Rare Diseases—Mitochondria in the Focus
Paß, T., Wiesner, R. J., & Pla‐Martín, D. (2021) · Frontiers in Molecular Biosciences · doi:10.3389/fmolb.2021.676187 · Cited by 37
Restoration of BDNF, DARPP32, and D2R Expression Following Intravenous Infusion of Human Immature Dental Pulp Stem Cells in Huntington’s Disease 3-NP Rat Model
Wenceslau, C. V., de Souza, D. M., Mambelli-Lisboa, N. C., Ynoue, L. H., Araldi, R. P., da Silva, J. M., Pagani, E., Haddad, M. S., & Kerkis, I. (2022) · Cells · doi:10.3390/cells11101664 · Cited by 36
Cytochrome c oxidase isoform IV‐2 is involved in 3‐nitropropionic acid‐induced toxicity in striatal astrocytes
Singh, S., Misiak, M., Beyer, C., & Arnold, S. (2009) · Glia · doi:10.1002/glia.20864 · Cited by 36
Pioglitazone suppresses neuronal and muscular degeneration caused by polyglutamine-expanded androgen receptors
Iida, M., Katsuno, M., Nakatsuji, H., Adachi, H., Kondo, N., Miyazaki, Y., Tohnai, G., Ikenaka, K., Watanabe, H., Yamamoto, M., et al. (2014) · Human Molecular Genetics · doi:10.1093/hmg/ddu445 · Cited by 36
Imaging and spectroscopic approaches to probe brain energy metabolism dysregulation in neurodegenerative diseases
Bonvento, G., Valette, J., Flament, J., Mochel, F., & Brouillet, E. (2017) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1177/0271678x17697989 · Cited by 38
Cdk5-mediated mitochondrial fission: A key player in dopaminergic toxicity in Huntington's disease
Cherubini, M., Puigdellívol, M., Alberch, J., & Ginés, S. (2015) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2015.06.025 · Cited by 38
Neuroprotective effect of zVAD against the neurotoxin 3-nitropropionic acid involves inhibition of calpain
Bizat, N., Galas, M., Jacquard, C., Boyer, F., Hermel, J., Schiffmann, S. N., Hantraye, P., Blum, D. L., & Brouillet, E. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.04.030 · Cited by 36
Protective effects of S-nitrosoglutathione against neurotoxicity of 3-nitropropionic acid in rat
Ju, T., Yang, Y.-T. C., & Yang, D. (2004) · Neuroscience Letters · doi:10.1016/j.neulet.2004.03.028 · Cited by 36
TMEM65 functions as the mitochondrial Na+/Ca2+ exchanger
Zhang, J., Chang, Y.-C., Lai, P.-H., Yeh, H., Tsai, C.-W., Huang, Y.-L., Liu, T., Lee, I., Foulon, N., Xu, Y., et al. (2025) · Nature Cell Biology · doi:10.1038/s41556-025-01721-x · Cited by 36
Neuroprotective Effects of Calmodulin Peptide 76‐121aa: Disruption of Calmodulin Binding to Mutant Huntingtin
Dudek, N. L., Dai, Y., & Muma, N. A. (2009) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00258.x · Cited by 35
The InsP3 receptor: its role in neuronal physiology and neurodegeneration
Banerjee, S., & Hasan, G. (2005) · BioEssays · doi:10.1002/bies.20298 · Cited by 35
Genotype‐dependent priming to self‐ and xeno‐cannibalism in heterozygous and homozygous lymphoblasts from patients with Huntington's disease
Mormone, E., Matarrese, P., Tinari, A., Cannella, M., Maglione, V., Farrace, M. G., Piacentini, M., Frati, L., Malorni, W., & Squitieri, F. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03998.x · Cited by 37
Asparagine and glutamine differ in their propensities to form specific side chain‐backbone hydrogen bonded motifs in proteins
Vasudev, P. G., Banerjee, M., Ramakrishnan, C., & Balaram, P. (2011) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.24001 · Cited by 35
Dithiol-based Compounds Maintain Expression of Antioxidant Protein Peroxiredoxin 1 That Counteracts Toxicity of Mutant Huntingtin
Pitts, A., Dailey, K. M., Newington, J. T., Chien, A., Arseneault, R., Cann, T., Thompson, L. M., & Cumming, R. C. (2012) · Journal of Biological Chemistry · doi:10.1074/jbc.m111.334565 · Cited by 35
Analysis of oxidative events induced by expanded polyglutamine huntingtin exon 1 that are differentially restored by expression of heat shock proteins or treatment with an antioxidant
Firdaus, W. J. J., Wyttenbach, A., Diaz‐Latoud, C., Currie, R. W., & Arrigo, A. (2006) · FEBS Journal · doi:10.1111/j.1742-4658.2006.05318.x · Cited by 37
Protective effects of brain-derived neurotrophic factor against neurotoxicity of 3-nitropropionic acid in rat cortical neurons
Wu, C., Hwang, C., & Yang, D. (2009) · NeuroToxicology · doi:10.1016/j.neuro.2009.03.008 · Cited by 34
Early dysfunction and progressive degeneration of the subthalamic nucleus in mouse models of Huntington's disease
Atherton, J. F., McIver, E. L., Mullen, M. R., Wokosin, D. L., Surmeier, D. J., & Bevan, M. D. (2016) · eLife · doi:10.7554/elife.21616 · Cited by 35
Targeting Mitochondrial Network Disorganization is Protective in C. elegans Models of Huntington’s Disease
Machiela, E., Rudich, P. D., Traa, A., Anglas, U., Soo, S. K., Senchuk, M. M., & Raamsdonk, J. M. V. (2021) · Aging and Disease · doi:10.14336/ad.2021.0404 · Cited by 34
Boosting mitochondrial health to counteract neurodegeneration
Burtscher, J., Romani, M., Bernardo, G., Popa, T., Ziviani, E., Hummel, F. C., Sorrentino, V., & Millet, G. P. (2022) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2022.102289 · Cited by 36
Type 2 transglutaminase in Huntington’s disease: a double‐edged sword with clinical potential
Mastroberardino, P. G., & Piacentini, M. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02275.x · Cited by 34
Ku70 Alleviates Neurodegeneration in Drosophila Models of Huntington's Disease
Tamura, T., Sone, M., Iwatsubo, T., Tagawa, K., Wanker, E. E., & Okazawa, H. (2011) · PLoS ONE · doi:10.1371/journal.pone.0027408 · Cited by 34
Metabolic State Determines Sensitivity to Cellular Stress in Huntington Disease: Normalization by Activation of PPARγ
Jin, Y. N., Hwang, W. Y., Jo, C., & Johnson, G. V. W. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030406 · Cited by 34
Cellular and molecular mechanisms involved in the selective vulnerability of striatal projection neurons in Huntington's disease.
Pérez‐Navarro, E., Canals, J. M., Ginés, S., & Alberch, J. (2006) · PubMed · doi:10.14670/hh-21.1217 · Cited by 34
Energy dysfunction in Huntington’s disease: insights from PGC-1α, AMPK, and CKB
Ju, T., Lin, Y., & Chern, Y. (2012) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-012-1025-2 · Cited by 34
Dysfunction of mitochondrial dynamics in the brains of scrapie-infected mice
Choi, H.-S., Choi, Y., Shin, H., Oh, J.-M., Park, J., Kim, J., Carp, R. I., Choi, E., & Kim, Y. (2014) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2014.04.069 · Cited by 33
Metabolism in Huntington’s disease: a major contributor to pathology
Singh, A., & Agrawal, N. (2021) · Metabolic Brain Disease · doi:10.1007/s11011-021-00844-y · Cited by 34
Interweaving of reactive oxygen species and major neurological and psychiatric disorders
Umare, M. D., Wankhede, N. L., Bajaj, K. K., Trivedi, R. V., Taksande, B. G., Umekar, M. J., Mahore, J., & Kale, M. B. (2021) · Annales Pharmaceutiques Françaises · doi:10.1016/j.pharma.2021.11.004 · Cited by 34
FK506 ameliorates cell death features in Huntington’s disease striatal cell models
Rosenstock, T. R., de Brito, O. M., Lombardi, V., Louros, S. R., Ribeiro, M., Almeida, S., Ferreira, I. L., Oliveira, C. R., & Rego, A. C. (2011) · Neurochemistry International · doi:10.1016/j.neuint.2011.04.009 · Cited by 33
Huntington's Disease — Making Connections
Greenamyre, J. T. (2007) · New England Journal of Medicine · doi:10.1056/nejmcibr067022 · Cited by 33
Self-citation
Reduction in Cerebral Atrophy Associated with Ethyl-Eicosapentaenoic Acid Treatment in Patients with Huntington's Disease
Puri, B. K., Bydder, G., Manku, M. S., Clarke, A., Waldman, A. D., & Beckmann, C. F. (2008) · Journal of International Medical Research · doi:10.1177/147323000803600505 · Cited by 33
STIM1 Protein Activates Store-Operated Calcium Channels in Cellular Model of Huntington’s Disease
Vigont, V. A., Zimina, O. A., Глушанкова, Л. Н., Kolobkova, J. A., Ryazantseva, M., Mozhayeva, G. N., & Kaznacheyeva, E. V. (2014) · Acta Naturae · doi:10.32607/20758251-2014-6-4-40-47 · Cited by 32
Therapeutic approaches to preventing cell death in Huntington disease
Kaplan, A. R., & Stockwell, B. R. (2012) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2012.08.004 · Cited by 32
Mitochondrial calcium uptake capacity as a therapeutic target in the R6/2 mouse model of Huntington's disease
Perry, G. M., Tallaksen‐Greene, S. J., Kumar, A., Heng, M. Y., Kneynsberg, A., van Groen, T., Detloff, P. J., Albin, R. L., & Lesort, M. J. (2010) · Human Molecular Genetics · doi:10.1093/hmg/ddq247 · Cited by 33
Oxidative metabolism and Ca2+handling in isolated brain mitochondria and striatal neurons from R6/2 mice, a model of Huntington’s disease
Hamilton, J., Pellman, J. J., Brustovetsky, T., Harris, R. A., & Brustovetsky, N. (2016) · Human Molecular Genetics · doi:10.1093/hmg/ddw133 · Cited by 32
Are immunotherapies for Huntington’s disease a realistic option?
Denis, H. L., Lauruol, F., & Cicchetti, F. (2018) · Molecular Psychiatry · doi:10.1038/s41380-018-0021-9 · Cited by 32
D1R- and D2R-Medium-Sized Spiny Neurons Diversity: Insights Into Striatal Vulnerability to Huntington’s Disease Mutation
Bergonzoni, G., Döring, J., & Biagioli, M. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.628010 · Cited by 32
Zebrafish an experimental model of Huntington’s disease: molecular aspects, therapeutic targets and current challenges
Kumar, V., Singh, C., & Singh, A. (2021) · Molecular Biology Reports · doi:10.1007/s11033-021-06787-y · Cited by 32
A study of molecular changes relating to energy metabolism and cellular stress in people with Huntington’s disease: looking for biomarkers
Krzysztoń-Russjan, J., Zielonka, D., Jackiewicz, J., Kuśmirek, S., Bubko, I., Klimberg, A., Marcinkowski, T., & Anuszewska, E. (2012) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-012-9479-3 · Cited by 32
Novel therapeutic targets for Huntington’s disease
Hannan, A. J. (2005) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.9.4.639 · Cited by 32
Phenazine derivatives cause proteotoxicity and stress in C. elegans
Ray, A., Rentas, C., Caldwell, G. A., & Caldwell, K. A. (2014) · Neuroscience Letters · doi:10.1016/j.neulet.2014.09.055 · Cited by 32
Mutant Huntingtin induces activation of the Bcl-2/adenovirus E1B 19-kDa interacting protein (BNip3)
Sassone, J., Colciago, C., Marchi, P. M., Ascardi, C., Alberti, L., Pardo, A. D., Zippel, R., Sipione, S., Silani, V., & Ciammola, A. (2010) · Cell Death and Disease · doi:10.1038/cddis.2009.6 · Cited by 32
Catecholamine exocytosis is diminished in R6/2 Huntington’s disease model mice
Johnson, M. A., Villanueva, M., Haynes, C. L., Seipel, A. T., Buhler, L. A., & Wightman, R. M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.04908.x · Cited by 32
Partial loss of MCU mitigates pathology in vivo across a diverse range of neurodegenerative disease models
Twyning, M. J., Tufi, R., Gleeson, T. P., Kolodziej, K. M., Campesan, S., Terriente-Félix, A., Collins, L., Lazzari, F. D., Giorgini, F., & Whitworth, A. J. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.113681 · Cited by 31
Pharmacological protein targets in polyglutamine diseases: Mutant polypeptides and their interactors
Margulis, B. A., Vigont, V. A., Lazarev, V. F., Kaznacheyeva, E. V., & Guzhova, I. V. (2013) · FEBS Letters · doi:10.1016/j.febslet.2013.05.022 · Cited by 32
Emerging Role of NLRP3 Inflammasome/Pyroptosis in Huntington’s Disease
Paldino, E., & Fusco, F. R. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23158363 · Cited by 31
Atorvastatin attenuates mitochondrial toxin‐induced striatal degeneration, with decreasing iNOS/c‐Jun levels and activating ERK/Akt pathways
Lee, S., Chu, K., Park, J., Hong, N. H., Im, W., Kang, L., Han, Z., Jung, K., Kim, M., & Kim, M. (2007) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2007.05044.x · Cited by 31
Activating mitochondrial regulator PGC-1α expression by astrocytic NGF is a therapeutic strategy for Huntington's disease
Chen, L., Horng, L., Wu, C.-L., Sung, H., & Wu, R.-T. (2012) · Neuropharmacology · doi:10.1016/j.neuropharm.2012.05.019 · Cited by 31
The chicken or the egg: mitochondrial dysfunction as a cause or consequence of toxicity in Huntington’s disease
Polyzos, A. A., & McMurray, C. T. (2016) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2016.09.003 · Cited by 31
Increased mitochondrial respiration maintains the mitochondrial membrane potential and promotes survival of cerebellar neurons in an endogenous model of glutamate receptor activation
Garcı́a, O., Almeida, Á., Massieu, L., & Bolaños, J. P. (2004) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2004.02851.x · Cited by 31
Elucidating a normal function of huntingtin by functional and microarray analysis of huntingtin-null mouse embryonic fibroblasts
Zhang, H., Das, S., Li, Q., Dragatsis, I., Repa, J. J., Zeitlin, S. O., Hajnóczky, G., & Борисович, Б. И. (2008) · BMC Neuroscience · doi:10.1186/1471-2202-9-38 · Cited by 31
Neurodegenerative disorders, metabolic icebergs, and mitohormesis
Phillips, M. C. L., & Picard, M. A. (2024) · Translational Neurodegeneration · doi:10.1186/s40035-024-00435-8 · Cited by 31
Mitochondria in aging and age-associated diseases
Pahal, S., Mainali, N., Balasubramaniam, M., Reis, R. J. S., & Ayyadevara, S. (2025) · Mitochondrion · doi:10.1016/j.mito.2025.102022 · Cited by 32
Mitochondrial functional alterations in relation to pathophysiology of Huntington’s disease
Pandey, M., Mohanakumar, K. P., & Rajamma, U. (2010) · Journal of Bioenergetics and Biomembranes · doi:10.1007/s10863-010-9288-5 · Cited by 30
Licofelone attenuates quinolinic acid induced Huntington like symptoms: Possible behavioral, biochemical and cellular alterations
Kalonia, H., Kumar, P., & Kumar, A. (2011) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2011.01.003 · Cited by 30
Glutamate‐induced alterations in Ca2+ signaling are modulated by mitochondrial Ca2+ handling capacity in brain slices of R6/1 transgenic mice
Rosenstock, T. R., Bertoncini, C. R. A., Teles, A. V. F. F., Hirata, H., Fernandes, M. J. D. S., & Smaili, S. S. (2010) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.2010.07268.x · Cited by 30
Mitochondrial DNA levels in Huntington disease leukocytes and dermal fibroblasts
Jędrak, P., Krygier, M., Tońska, K., Drozd, M., Kaliszewska, M., Bartnik, E., Sołtan, W., Sitek, E. J., Stanisławska‐Sachadyn, A., Limon, J., et al. (2017) · Metabolic Brain Disease · doi:10.1007/s11011-017-0026-0 · Cited by 30
Ethyl-EPA in Huntington disease—Potentially relevant mechanism of action
Murck, H., & Manku, M. (2007) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2006.10.020 · Cited by 30
Exploring molecular mechanisms, therapeutic strategies, and clinical manifestations of Huntington’s disease
Shafie, A., Ashour, A. A., Anwar, S., Anjum, F., & Hassan, M. I. (2024) · Archives of Pharmacal Research · doi:10.1007/s12272-024-01499-w · Cited by 29
Treadmill exercise rescues mitochondrial function and motor behavior in the CAG140 knock-in mouse model of Huntington's disease
Caldwell, C. C., Petzinger, G. M., Jakowec, M. W., & Cadenas, E. (2019) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2019.108907 · Cited by 29
The amyloid state of proteins: A boon or bane?
Hassan, M. N., Nabi, F., Khan, A. N., Hussain, M. S., Siddiqui, W. A., Uversky, V. N., & Khan, R. H. (2022) · International Journal of Biological Macromolecules · doi:10.1016/j.ijbiomac.2022.01.115 · Cited by 30
The Emerging Landscape of Natural Small-molecule Therapeutics for Huntington’s Disease
Bhat, S. A., Ahamad, S., Dar, N. J., Siddique, Y. H., & Nazir, A. (2023) · Current Neuropharmacology · doi:10.2174/1570159x21666230216104621 · Cited by 29
Targeting Mitochondrial Sirtuins in Age-Related Neurodegenerative Diseases and Fibrosis
Xiao, H., Xie, Y., Xi, K., Xie, J., Liu, M., Zhang, Y., Cheng, Z., Wang, W., Guo, B., & Wu, S. (2023) · Aging and Disease · doi:10.14336/ad.2023.0203 · Cited by 29
Transgenic Animal Models of Huntington’s Disease
Yang, S., & Chan, A. W. S. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2010_105 · Cited by 29
Excitotoxicity in Huntington disease
Raymond, L. A. (2003) · Clinical Neuroscience Research · doi:10.1016/s1566-2772(03)00054-9 · Cited by 31
Emerging chemotherapeutic strategies for Huntington’s disease
Ryu, H., & Ferrante, R. J. (2005) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.10.2.345 · Cited by 30
Induction of apoptosis in cells expressing exogenous Hippi, a molecular partner of huntingtin-interacting protein Hip1
Majumder, P., Chattopadhyay, B., Mazumder, A. G., Das, P. K., & Bhattacharyya, N. P. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.11.003 · Cited by 29
Correction: Iron Accumulates in Huntington’s Disease Neurons: Protection by Deferoxamine
Chen, J., Marks, E. S., Lai, B. C. H., Zhang, Z., Duce, J. A., Lam, L. Q., Volitakis, I., Bush, A. I., Hersch, S. M., & Fox, J. H. (2013) · PLoS ONE · doi:10.1371/annotation/67f555f5-35b7-4468-8bab-26d518942803 · Cited by 29

Authors: Panov, A. V., Gutekunst, C.-A., Leavitt, B. R., Hayden, M. R., Burke, J. R., Strittmatter, W. J., & Greenamyre, J. T.
Affiliations: Emory University (US)
University of British Columbia (CA)
Duke Medical Center (US)
Corresponding author: Greenamyre, J. Timothy
ORCID: Panov, Alexander V.
Gutekunst, Claire-Anne
Leavitt, Blair R.
Hayden, Michael R.
Burke, James R.
Greenamyre, J. Timothy
Venue: Nature Neuroscience
Publisher: Springer Science and Business Media LLC
Published: 2002-07-01
Volume: 5
Issue: 8
Pages: 731-736
ISSN: 1097-6256 (ISSN-L)
1546-1726
DOI: 10.1038/nn884
OpenAlex: W1972771185
Cited by: 1,030
References: 35
Citations by year: 2026: 16 · 2025: 23 · 2024: 26 · 2023: 27 · 2022: 30 · 2021: 49 · 2020: 29 · 2019: 35 · 2018: 39 · 2017: 23 · 2016: 45 · 2015: 35 · 2014: 48 · 2013: 33 · 2012: 68
FWCI: 19.24
Type: journal article
Language: en
Open access: closed
Licence: www.springer.com/tdm (tdm)
Locations: Nature Neuroscience (publishedVersion)
PubMed (publishedVersion)
Funders: National Institutes of Health (5r01ag014648-05)
National Institute on Aging (AG14648)
Topics: Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Genetic Neurodegenerative Diseases
Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mitochondrial Function and Pathology
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Hereditary Neurological Disorders
Keywords: Huntington's disease, mitochondrial calcium handling, polyglutamine expansion, mutant huntingtin, mitochondrial membrane potential, mitochondrial depolarization, neurodegeneration, transgenic mice, early pathogenesis
MeSH terms: Huntingtin Protein, Animals, Brain, Brain Chemistry, Calcium, Cell Line, Disease Models, Animal, Humans, Huntington Disease, Intracellular Membranes, Lymphocytes, Membrane Potentials, Mice, Transgenic, Microscopy, Electron, Mitochondria, Nerve Tissue Proteins, Nuclear Proteins, Recombinant Fusion Proteins, Trinucleotide Repeat Expansion, Mice

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Early mitochondrial calcium defects in Huntington's disease are a direct effect of polyglutamines

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks